Immunotherapy Study for Metastatic Renal Cell Cancer

NCT02035358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Metastatic Clear-cell Renal Cancer
Recurrent Renal Cell Carcinoma
Refractory Renal Cell Carcinoma
Metastatic Kidney Cancer

Interventions

BIOLOGICAL: HyperAcute®-Renal (HAR) Immunotherapy

Sponsor

NewLink Genetics Corporation